Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111839
Status:
COMPLETED
Last Update Posted:
2018-04-06
First Post:
2005-05-26
Brief Title:
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Sponsor:
EMD Serono
Organization:
EMD Serono
Study Overview
Official Title:
Randomized Phase II Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 Matuzumab in Combination With Pemetrexed or Pemetrexed Alone as Second-Line Treatment for Stage IIIBIV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes Gemcitabine and Vinorelbine
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This open-label multicenter randomized controlled Phase II study is planned to answer questions about how the drug matuzumab EMD 72000 works and is part of an effort aimed to develop better treatment for advanced lung cancer by combining matuzumab a monoclonal antibody with a chemotherapy treatment called pemetrexed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-000899-32 | EUDRACT_NUMBER | None | None |